April 16th 2025
In quarter 1 of 2025, nogapendekin alfa inbakicept received regenerative medicine advanced therapy designation for lymphopenia.
No Improvement in OS With Extended Vs Standard Lymphadenectomy in MIBC
June 6th 2023Findings from the phase 3 SWOG S1011 trial highlight no significant differences between extended lymphadenectomy vs standard lymphadenectomy in terms of disease-free survival in patients with muscle-invasive breast cancer.
Enfortumab/Pembrolizumab Dosing Schedule ‘Groundbreaking’ in Urothelial Cancer
April 4th 2023Nazy Zomorodian, NP, spoke with CancerNetwork® about the unique dosing schedule of enfortumab vedotin plus pembrolizumab following its accelerated approval by the FDA in advanced/metastatic urothelial cancer.
Enfortumab Vedotin Combo Gets Accelerated FDA Nod for Urothelial Cancer
April 3rd 2023Results from cohort K of the phase 1b/2 KEYNOTE-869 trial led to the accelerated approval of enfortumab vedotin plus pembrolizumab in patients with locally advanced or metastatic urothelial cancer who cannot receive cisplatin-based chemotherapy.
Genomic Analysis Yields ‘Hypothesis Generating’ Data in Bladder Cancer Subtype
February 26th 2023An expert from Chase Comprehensive Cancer Center discusses how findings from a genomic analysis of the phase 2 BLASST-1 trial may identify biomarkers of response and resistance to nivolumab/chemotherapy in muscle-invasive bladder cancer.
Atezolizumab/Chemo Demonstrates Survival Trend in Urothelial Carcinoma
February 18th 2023Results from the phase 3 IMvigor130 trial reveal a trend towards overall survival improvement when atezolizumab plus chemotherapy was given to patients with locally advanced or metastatic urothelial carcinoma vs placebo.
Sacituzumab Govitecan Yields Consistent Benefit in Platinum-Ineligible mUC
February 18th 2023Data from the phase 2 TROPHY-U-01 trial support further evaluation of sacituzumab govitecan in patients with metastatic urothelial cancer following immune checkpoint inhibitor therapy, according to the lead investigator.